Summit Trail Advisors LLC Buys 403 Shares of Moderna, Inc. (NASDAQ:MRNA)

Summit Trail Advisors LLC boosted its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 12.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,558 shares of the company’s stock after acquiring an additional 403 shares during the period. Summit Trail Advisors LLC’s holdings in Moderna were worth $423,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Hobbs Group Advisors LLC acquired a new position in Moderna in the fourth quarter valued at about $664,000. Illinois Municipal Retirement Fund raised its position in shares of Moderna by 22.1% in the 1st quarter. Illinois Municipal Retirement Fund now owns 51,791 shares of the company’s stock valued at $5,519,000 after buying an additional 9,360 shares in the last quarter. Swedbank AB bought a new stake in shares of Moderna during the 1st quarter worth approximately $3,315,000. Wellington Management Group LLP boosted its position in shares of Moderna by 28.8% during the 4th quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock worth $718,584,000 after acquiring an additional 1,614,460 shares in the last quarter. Finally, Los Angeles Capital Management LLC bought a new position in Moderna in the first quarter valued at approximately $2,693,000. 75.33% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

MRNA has been the subject of several recent analyst reports. Royal Bank of Canada restated a “sector perform” rating and set a $75.00 target price on shares of Moderna in a research note on Thursday, September 19th. Barclays dropped their target price on shares of Moderna from $155.00 to $125.00 and set an “overweight” rating for the company in a report on Monday, September 16th. Evercore ISI reiterated an “in-line” rating and set a $120.00 price objective on shares of Moderna in a research report on Thursday, June 27th. Hsbc Global Res raised shares of Moderna from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 28th. Finally, The Goldman Sachs Group dropped their price target on Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a research note on Monday, September 16th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $100.44.

Moderna Stock Down 2.4 %

Shares of NASDAQ MRNA opened at $64.14 on Tuesday. The company’s 50 day moving average price is $88.92 and its 200-day moving average price is $110.71. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $170.47. The company has a market capitalization of $24.58 billion, a P/E ratio of -4.09 and a beta of 1.67.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.47) by $0.14. The business had revenue of $241.00 million for the quarter, compared to analyst estimates of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. During the same quarter in the previous year, the business earned ($3.62) earnings per share. Moderna’s revenue for the quarter was down 29.9% on a year-over-year basis. Equities analysts forecast that Moderna, Inc. will post -9.52 earnings per share for the current year.

Insider Activity

In other Moderna news, CFO James M. Mock sold 689 shares of Moderna stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $118.24, for a total value of $81,467.36. Following the completion of the sale, the chief financial officer now directly owns 7,269 shares in the company, valued at $859,486.56. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Moderna news, CFO James M. Mock sold 689 shares of the firm’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $118.24, for a total value of $81,467.36. Following the completion of the sale, the chief financial officer now directly owns 7,269 shares in the company, valued at $859,486.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, President Stephen Hoge sold 15,000 shares of the company’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $121.12, for a total transaction of $1,816,800.00. Following the transaction, the president now owns 1,442,089 shares in the company, valued at approximately $174,665,819.68. The disclosure for this sale can be found here. Insiders have sold 93,158 shares of company stock valued at $11,167,312 in the last ninety days. 15.70% of the stock is owned by company insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.